[在三级医院的ICU患者中,具有关键优先级的阴性细菌]
Andrés Humberto Uc-Cachón1, Gloria María Molina-Salinas1, Angel de Jesús Dzul-Beh1
1Instituto Mexicano del Seguro Social, Hospital de Especialidades No. 1 "Lic. Ignacio García Téllez", Unidad de Investigación Médica Yucatán. Mérida, Yucatán, México.
在重症监护病房 (ICU) 中,抗菌素耐药性 (AMR) 是一个主要问题. 在ICU中,格兰阴性细菌 (GNB) 呈现出高耐药率,其中Klebsiella pneumoniae和Acinetobacter baumannii占主导地位.
科学领域:
- 传染性疾病 传染性疾病
- 微生物学 微生物学
- 临界护理医学 临界护理医学
背景情况:
- 重症监护病房 (ICU) 是抗菌素耐药性 (AMR) 出现和传播的关键环境.
- 阴性细菌 (GNB) 是ICU患者感染的主要致病原体,这给治疗带来了重大挑战.
研究的目的:
- 调查从ICU患者中隔离的GNB中AMR的流行率和时间趋势.
- 从2019年到2021年,分析位于尤卡坦州梅里达的一家三级护理医院GNB的耐药性模式.
主要方法:
- 对新生儿,儿科和成人ICU的所有细菌学样本的实验室报告的回顾性审查.
- 数据收集时间从2019年1月1日到2021年12月31日.
主要成果:
- 总共有433个GNB分离物被确定,其中Klebsiella pneumoniae是最常见的 (27.02%).
- 对安皮西林 (89.48%) 和素 (高达93.81%) 和托布拉米辛 (58.06%) 观察到高耐药率.
- 显著比例的GNB表现出多抗药性 (73.90%) 和广泛抗药性 (47.54%的Acinetobacter baumannii) 个人资料. A. baumannii的碳烯耐药性为80.33%,而K. pneumoniae菌株的83.76%是产生ESBL的.
结论:
- 该研究强调了在ICU中存在多药耐药性和广泛耐药性GNB的普遍性.
- 这些发现可以为开发有针对性的实证抗生素疗法提供信息,并加强ICU内的感染控制策略.
更多相关视频
11:32Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria
Published on: February 23, 2014
03:22Author Spotlight: Advancing Pathogen Detection and Disease Assessment in Real-Time Using M-ROSE
Published on: March 1, 2024
相关概念视频
Acute Pyelonephritis II: Diagnostic Studies and Management
Urinary Tract Infection III: Diagnostic Studies and Interprofessional Care
Pneumonia IV: Management
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
Endocarditis IV: Nursing Management
Urine Studies II: Urine Culture and Sensitivity Test
Healthcare Associated Infections I: Iatrogenic, Exogenic and Endogenic
HAIs significantly increase the cost of health care. Extended stays in healthcare institutions, increased disability, increased costs of medications, including specialized antibiotics, and prolonged recovery times add to the patient's expenses and the healthcare institution and funding bodies.
